ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Knight Therapeutics Inc

Knight Therapeutics Inc (GUD)

9,33
0,13
(1,41%)
Geschlossen 11 Juni 10:12PM

Knight Therapeutics Inc (GUD) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
9,33
( 1,41% )
Gebot
9,25
Fragen
9,41
Volumen
172.346
9,15 Tagesbereich 9,38
5,66 52-Wochen-Bereich 9,38
Marktkapitalisierung
Handelsende
9,20
Handelsbeginn
9,15
Letzte Trade
6
@
9.33
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
$ 90.438
Ausgegebene Aktien
98.179.361
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
162,8
Gewinn pro Aktie (EPS)
0,06
Erlöse (LTM)
510,45M
Nettogewinn (LTM)
5,61M

Über Knight Therapeutics Inc

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma... Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Hauptsitz
Montreal, Canada
Gegründet
2026
Knight Therapeutics Inc is listed in the Healthcare sector of the Toronto Börse with ticker GUD. The last closing price for Knight Therapeutics was $9,20. Over the last year, Knight Therapeutics shares have traded in a share price range of $ 5,66 to $ 9,38.

Knight Therapeutics currently has 98.179.361 shares in issue. The market capitalisation of Knight Therapeutics is $916,01 million. Knight Therapeutics has a price to earnings ratio (PE ratio) of 162.80.

GUD Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
11.2515.47029702978.089.388.081156068.82515399CS
40.687.86127167638.659.387.88856328.47465675CS
123.1851.70731707326.159.386.12958777.7590144CS
263.4358.13559322035.99.385.66913796.94441039CS
523.3355.569.385.66747226.61891288CS
1564.3687.72635814894.979.384.35713495.84058799CS
2604.0476.3705103975.299.384.281213265.47475797CS

GUD - Frequently Asked Questions (FAQ)

What is the current Knight Therapeutics Inc share price?
The current share price of Knight Therapeutics Inc is $ 9,33
How many Knight Therapeutics Inc shares are in issue?
Knight Therapeutics Inc has 98.179.361 shares in issue
What is the market cap of Knight Therapeutics Inc?
The market capitalisation of Knight Therapeutics Inc is CAD 916,01M
What is the 1 year trading range for Knight Therapeutics Inc share price?
Knight Therapeutics Inc has traded in the range of $ 5,66 to $ 9,38 during the past year
What is the PE ratio of Knight Therapeutics Inc?
The price to earnings ratio of Knight Therapeutics Inc is 162,8
What is the cash to sales ratio of Knight Therapeutics Inc?
The cash to sales ratio of Knight Therapeutics Inc is 1,77
What is the registered address of Knight Therapeutics Inc?
The registered address for Knight Therapeutics Inc is 100 Boul. Alexis-Nihon, Montreal, Quebec, H4M 2P2
What is the Knight Therapeutics Inc website address?
The website address for Knight Therapeutics Inc is www.knighttx.com
Which industry sector does Knight Therapeutics Inc operate in?
Knight Therapeutics Inc operates in the Pharmaceuticals sector

GUD Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen